4
Changes in Ownership
Roivant Sciences Ltd. Filed Acc 0001635088-26-000116
President & Immunovant CEO sold 200,000 shares at an average $35.11 ($7,022,668)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Venker Eric President & Immunovant CEO | 2026-10-20 | Sale 10b5-1 | −185,856 | $35.09 | $6,521,687 | 1,413,298 | D: show line 1 in the form |
| Venker Eric President & Immunovant CEO | 2026-10-20 | Sale 10b5-1 | −14,144 | $35.42 | $500,980 | 1,399,154 | D: show line 2 in the form |
| Open-market sales · 200,000 sh · avg $35.11 · $7,022,668 | |||||||
Loading xslF345X06/wk-form4_1792709044.xml…